Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026)
Elanco Animal Health (ELAN) posted Total Non-Current Liabilities of $6.3 billion for Q1 2026, down 3.87% sequentially from $6.5 billion in Q4 2025, and up 2.52% YoY from $6.1 billion in Q1 2025.
Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Elanco Animal Health has reported Total Non-Current Liabilities for 10 years, with the latest figure at $6.3 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 2.52% year-over-year to $6.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.3 billion (up 2.52% YoY) and the FY2025 annual result came in at $6.5 billion, up 4.68% from the prior year.
- Total Non-Current Liabilities fell to $6.3 billion in Q1 2026 per ELAN's latest filing, from $6.5 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $8.4 billion in Q1 2022 and troughed at -$193.0 million in Q2 2022.
- A 5-year average of $6.7 billion and a median of $7.4 billion in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities sank 102.24% in 2022, then jumped 4226.94% in 2023.
- Over 5 years, Total Non-Current Liabilities stood at $8.0 billion in 2022, then declined by 3.07% to $7.7 billion in 2023, then decreased by 19.57% to $6.2 billion in 2024, then climbed by 4.68% to $6.5 billion in 2025, then dropped by 3.87% to $6.3 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $6.3 billion, $6.5 billion, and $6.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.42 Bn |
| Mar 31, 2026 | 6.26 Bn |
| Dec 31, 2025 | 6.51 Bn |
| Sep 30, 2025 | 6.20 Bn |
| Jun 30, 2025 | 6.33 Bn |
| Mar 31, 2025 | 6.10 Bn |
| Dec 31, 2024 | 6.22 Bn |
| Sep 30, 2024 | 6.17 Bn |
| Jun 30, 2024 | 7.36 Bn |
| Mar 31, 2024 | 7.49 Bn |
| Dec 31, 2023 | 7.73 Bn |
| Sep 30, 2023 | 7.78 Bn |
| Jun 30, 2023 | 7.97 Bn |
| Mar 31, 2023 | 8.04 Bn |
| Dec 31, 2022 | 7.97 Bn |
| Sep 30, 2022 | 7.98 Bn |
| Jun 30, 2022 | -193.00 Mn |
| Mar 31, 2022 | 8.40 Bn |
| Dec 31, 2021 | 8.71 Bn |
| Sep 30, 2021 | 8.66 Bn |